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A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein
gp120 of the human immunodeficiency virus. These epitopes are exposed during conforma-
tional changes when gp120 binds to its primary receptor CD4. Based on chemical modification
of lysine and arginine residues followed by mass spectrometric analysis, we determined the
epitope on gp120 recognized by the human monoclonal antibody 559/64-D, which was
previously found to be specific for the CD4 binding domain. Twenty-four lysine and arginine
residues in recombinant full-length glycosylated gp120 were characterized; the relative
reactivities of two lysine residues and five arginine residues were affected by the binding of
559/64-D. The data show that the epitope is discontinuous and is located in the proximity of
the CD4-binding site. Additionally, the reactivities of a residue that is located in the secondary
receptor binding region and several residues distant from the CD4 binding site were also
altered by Ab binding. These data suggest that binding of 559/64-D induced conformational
changes which result in altered surface exposure of specific amino acids distant from the
CD4-binding site. Consequently, binding of 559/64-D to gp120 affects not only the CD4-
binding site, which is recognized as the epitope, but appears to have a global effect on surface
exposed residues of the full-length glycosylated gp120. (J Am Soc Mass Spectrom 2010, 21,
1687–1698) © 2010 Published by Elsevier Inc. on behalf of American Society for Mass SpectrometryShortly after infection with the human immunodefi-ciency virus (HIV-1), patients develop antibodies(Abs) against the virus; however, ultimately the
immune system fails to control the virus, leading to
acquired immune deficiency syndrome (AIDS). The char-
acterization of neutralizing antibodies, which are gener-
ated by most individuals infected with HIV and are a
major component of host defense against the virus, will
provide insight on the structural features of antigen-
recognition and the development of neutralization resis-
tance. HIV neutralizing antibodies are mainly directed
against the transmembrane protein gp41 and the envelope
protein gp120 [1, 2]. Both gp41 and gp120 are expressed as
the precursor protein gp160, which matures into the
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doi:10.1016/j.jasms.2010.03.031individual proteins by cleavage. The proteins remain
noncovalently associated and form a trimeric oligomer
(gp41/gp120)3 [3]. During the initial step of infection, a
noncovalent complex is formed between gp120 and its
primary receptor CD4, which is located as a transmem-
brane glycoprotein on circulating CD4 lymphocytes and
monocytes [4, 5]. Subsequently, conformational changes
occur in gp120 and CD4, which expose the binding site on
the surface of gp120 for a coreceptor of the chemokine
receptor family. After formation of the complex of gp120/
CD4/coreceptor, additional conformational changes in
gp41 occur, facilitating the fusion of the viral membrane
with the host cell membrane and entry of the viral RNA
into the cell [6, 7].
Homology analyses of the glycoprotein gp120 have
identified five conserved regions and five variable re-
gions [8]. The conserved regions form the core of the
protein (the core consists of Gly-Ala-Gly tripeptide
substitutions for 67 V1/V2 loop residues and 32 V3 loop
residues; and the removal of all sugar groups beyond
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1688 HAGER-BRAUN ET AL. J Am Soc Mass Spectrom 2010, 21, 1687–1698the linkages between the two core N-acetylglucosamine
residues and deletions of 52 and 19 residues from the N
and C termini, respectively) [9], and disulfide bridges in
the variable regions result in the formation of flexible
loops [10]. Both conserved and variable regions are
extensively glycosylated with 50% of the mass of the
glycoprotein derived from glycans [10–12]. The vari-
able loops and the carbohydrate moieties on the surface
of gp120 shield conserved regions that are functionally
important and are only accessible after a sequence of
conformational changes in the envelope protein. Nev-
ertheless, several regions are targets for neutralizing
antibodies, in particular the variable loops V1/V2 and
V3, the conserved region C4 (which contains residues
involved in CD4-binding), the CD4 binding site (CD4-
BS, formed by the inner domain, the outer domain and
part of the bridging sheet of gp120), and the CD4-
induced binding site for the coreceptor [13–19]. Map-
ping of epitopes on gp120, mainly through competition
analyses and mutagenic analyses, resulted in the iden-
tification of a “neutralizing face” recognized by neutral-
izing antibodies, a “non-neutralizing face” recognized
by non-neutralizing antibodies and a “silent face,” which
has a very poor immunogenicity due to its extensive
glycosylation [15, 20]. Although a significant number of
neutralizing antibodies targeted against epitopes in T-cell
line adapted (TCLA) HIV strains have been characterized,
only a few antibodies are capable of neutralizing primary
HIV isolates in vitro (reviewed in [1, 2, 21].
The reasons for the differences in neutralization
sensitivity are not fully understood, but apparently
laboratory-adapted viruses and primary isolates adopt
different configurations of the trimeric envelope com-
plex [21]. Studies also suggest that various neutralizing
antibodies might recognize different conformations of
gp120 that do not necessarily correspond to the confor-
mation of the truncated deglycosylated gp120 core in
complex with CD4. Analysis of the thermodynamics of
gp120-CD4 association showed large enthalpy and en-
tropy changes indicating significant flexibility of gp120
in the unbound form and conformational changes upon
binding of the primary receptor [22]. Based on the
crystal structure, gp120 in the bound state has a narrow
binding pocket for CD4 [9]. Xiang et al. described a
gp120 mutant with the amino acid substitution S375W
that adopts a narrow conformation at the CD4-BS in the
absence of CD4 [23]. This S375Wmutant did not bind any
of the tested Abs directed against the CD4-BS, also indi-
cating different conformations of the CD4 binding site in
absence and presence of the primary receptor. More
recently, Kwong and coworkers showed by crystallo-
graphic structure determinations that CD4 induces a con-
formational change in gp120 [24], and that the conforma-
tion of the bridging sheet in gp120 undergoes significant
conformational change upon CD4 binding [25]. Molecular
dynamics simulations also suggest different conforma-
tions for gp120 in the bound and unbound states [26].
Recently, the crystal structure of a SIV gp120-core, which
represents the unliganded state of the glycoprotein, waspublished [27]. Comparison of the structure with the
liganded HIVHXBc2 gp120-core showed significant confor-
mational differences of the inner domain. In the unligan-
ded conformation, the constituents of the CD4-binding
domain form a cavity, which is long and narrow com-
pared with the open cavity in the CD4-bound HIV-gp120.
Here we present the mapping of the epitope of
full-length, non-deglycosylated gp120 recognized by
the human monoclonal antibody (MAb) 559/64-D by
chemical modification of arginine (R) and lysine (K)
residues and subsequent mass spectrometric analyses.
Immunochemical studies suggested that the epitope of
this MAb is located in the CD4-BS [28], and functional
studies show that this MAb is able to neutralize several
TCLA-adapted strains of HIV [29]. Interestingly, this
and other MAbs to the CD4-binding site have been
shown to prevent proteolysis of gp120 and subsequent
presentation of gp120 to CD4-T-cells [30–33] that sera
with broadly cross-neutralizing Abs have anti-CD4-BS
Abs, which can be responsible or contribute to the
breadth of neutralization [34, 35]. MAb 559/64-D may
also have characteristics similar to the anti-CD4-BS
MAb F105, which is often used in many studies and is
also not broadly neutralizing for non-TLCA strains [36].
The CD4-BS is conserved among HIV strains and is
functionally required for the initial step of infection.
Consequently, it is important to determine the binding
site of neutralizing and non-neutralizing Abs such as
the MAb 559/64-D targeting the CD4-BS to understand
the relationship between gp120-structure and neutral-
ization potency of the Abs.
In this study, gp120 bound to the antibody 559/64-D,
as well as free in solution, was modified by either lysine
acetylation or arginine hydroxyphenylglyoxylation, and
differences in the modification pattern were used to
indicate interaction sites between the antibody and its
antigen. The acetylation of the -amino group at the
N-terminus of a protein and of the -amino group in
lysine residues has been previously used to characterize
the topology of proteins [37–40]. The derivatization of
arginine residues with hydroxyphenylglyoxal (HPG)
has been established as a modification to determine the
participation of arginines in the active site of proteins
and in the interaction site with a binding partner [41,
42]. In the present case, observed differences in reactiv-
ity of arginines and lysines are used as a measure of the
accessibility of the residue to the reagent. It should be
noted that this is not identical to surface accessibility as
changes in reactivity resulting from, for example changes
in pKa due to variations in residue reactivities (e.g., salt
bridges) are eliminated by taking the ratio of reactivity
in the bound and unbound states.
Experimental
Materials
The CHO-cell expressed glycoprotein gp120 from HIV
strain SF2 was purchased from Austral Biologicals (San
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559/64-D was produced as described in Karwowska et
al. [29]. Endoproteinases GluC, AspN, and LysC were
obtained from Roche Molecular Biologicals (Indianap-
olis, IN, USA), trypsin-(tosyl-amido-2-phenyl) ethyl-
chloromethyl ketone from Worthington Biochemical
(Freehold, NJ, USA) and PNGaseF from Roche Diag-
nostics (Mannheim, Germany) and Glyko (Novato, CA,
USA). Hydroxyphenylglyoxal was obtained from Pierce
(Rockford, IL, USA), iodoacetamide and -cyano-4-
hydroxycinnamic acid from Aldrich (Milwaukee, WI,
USA), and acetic anhydride and hexadeuteroacetic an-
hydride from Sigma (St. Louis, MO, USA).
Derivatization of Lysine Residues
HIV-gp120 and the MAb 559/64-D were combined and
incubated for 1 h at RT. A 2-fold molar excess of the
MAb compared to gp120 was used to assure that all
gp120 was bound to the antibody based on the dissoci-
ation constant of the complex (14  109 M) [29]. The
molar excesses that are necessary for the partial and the
complete acetylation of gp120 were determined by
acetylation of the protein with 1000-, 10,000-, and
200,000-fold molar excess and subsequent purification
by reversed-phase HPLC. The conditions were as fol-
lows: protein-C4-column (4.6 mm  250 mm; Vydac,
Hesperia, CA, USA) with a C4-guard column (Vydac);
flow rate 1 mL/min; A: 0.1% trifluoroacetic acid in
water, B: 0.09% trifluoroacetic acid, 10% water in ace-
tonitrile; gradient 10% B to 70% B over 50 min; 1
mL-fractions. The collected fractions were lyophilized,
re-dissolved in PBS, and analyzed by matrix-assisted
laser desorption/ionization (MALDI) mass spectrome-
try (MS). The purified protein was digested with the
endoproteinase GluC in 50 mM NH4HCO3 buffer at
37 °C and analyzed by MALDI/MS. Acetylated pep-
tides were identified by their mass shift of 42 Da. A
1000-fold and a 10,000-fold molar excess, respectively,
led to partial acetylation of gp120. With a molar excess
of 200,000, complete acetylation was observed. Note
that the molar excess does not include the aqueous
environment, which also reacts with acetic anhydride,
albeit at a slower rate than does the primary amine. To
ensure that the antigen-antibody complex remains in-
tact during modification, the antibody was immobilized
on cyanogen bromide-activated Sepharose beads (Pierce
Chemical Co. Rockford, IL, USA) as described previ-
ously [38], gp120 was added, and the Ab-Ag complex
was formed by incubation for 1 h at RT. Subsequently,
the beads were washed to remove any unbound protein
and analyzed by MALDI/MS for the presence of bound
gp120. The complex was then acetylated with 10,000-
fold molar excess acetic anhydride and washed again.
The subsequent analysis of the beads by MALDI/MS
showed that the acetylated gp120 was still affinity-
bound.
For differential modification of lysine residues, the
antigen-antibody complex in solution was initiallyacetylated with a 10,000-fold molar excess of acetic
anhydride. Under these conditions, the native confor-
mation of the protein was largely retained as indicated
by continued recognition by the antibody. The acety-
lated gp120/MAb complex was purified by reversed-
phase HPLC. Fractions containing the acetylated gp120
were combined and derivatized with a 200,000-fold
molar excess of hexadeuteroacetic anhydride. Under
these conditions, the protein became denatured, allow-
ing exhaustive acetylation. Acetylated residues were
accessible to the reagent in the native or complexed
state, while deuteroacetylated residues became accessi-
ble to the reagent only after denaturing the protein,
regardless of whether the protein was initially complexed
or non-complexed. The acetylated/trideuteroacetylated pro-
tein was again purified by HPLC. After lyophilization,
the protein was dissolved in 10 L 50% acetonitrile/
0.1% formic acid. The solution was diluted 1:5 with 50
mM ammonium bicarbonate (pH 8.3) and digested with
endoproteinase GluC (enzyme:substrate ratio 1:20) for
12 h at 37 °C. The solution was split into two equal
parts. One part was digested further with trypsin for 4 h
at 37 °C (enzyme:substrate ratio 1:20). The peptides in
both samples were deglycosylated with PNGaseF for
12 h at 37 °C. To reduce and alkylate the disulfide
bridges, DTT was added to a final concentration of 10
mM (ca. 25:1 M ratio of DTT per disulfide bond), and
the solution was incubated at 56 °C for 1 h. The peptides
were alkylated with 55 mM iodoacetamide for 45 min at
56 °C in the dark. Subsequently, the samples were
analyzed by MALDI/MS and liquid chromatography
(LC) electrospray ionization (ESI) MS/MS. All reactions
were performed in duplicate. The ratio of deuteroacety-
lated lysine containing peptide to non-deuteroacetylated
lysine containing peptide was determined from the
abundances of the extracted ion currents of the proton-
ated molecules.
Derivatization of Arginine Residues
For the formation of a noncovalent complex, HIV-gp120
and the MAb 559/64-D were incubated for 2 h at RT in
a 2:1 ratio with a final concentration of 3 pmol gp120/
L. Arginine residues were derivatized with 10 mM
HPG in 25 mM NaHCO3 for 18 h 30 min with rotation
at RT in the dark. As a control, gp120 was incubated
with 10 mM HPG in the absence of the MAb. After
derivatization, gp120 was purified from the antibody
and the excess HPG by reversed-phase HPLC. The
conditions were as follows: protein-C4-column (4.6 mm
250 mm; Vydac, Hesperia, CA, USA) with a C4-guard
column (Vydac); flow rate 1 mL/min; A: 0.1% trifluoro-
acetic acid in water, B: 0.1% trifluoroacetic acid in
acetonitrile; gradient: 2% B, 5 min; 2% B to 95% B, 50
min; 95% B, 5 min; collection of 1 mL fractions. After
lyophilization, the protein in each fraction was resus-
pended in 5 L 50% acetonitrile/0.1% formic acid and
analyzed by MALDI/MS. Fractions containing derivat-
ized gp120 were combined. Multiple reactions and
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Due to limited MAb availability, only single derivatiza-
tions under each set of conditions could be performed.
To determine the sites of derivatization, HPG-modified
gp120 was digested with various endoproteinases. A
100 pmol aliquot of modified gp120 was diluted 10-fold
to give a concentration of 5% acetonitrile and then
incubated with endoproteinase LysC at a ratio of 1:20 in
25 mM Tris-HCl (pH 8.0) for 18 h at 37 °C. The peptides
were deglycosylated with PNGaseF for 24 h at 30 °C.
Additionally, an aliquot of the deglycosylated LysC
digest was further digested with the endoproteinase
AspN at an enzyme:substrate ratio of 1:62.5 for 18 h at
35 °C. Equivalent changes in reactivity were observed
for specific residues determined from different reac-
tions and digested with different reagents.
MALDI/MS
Mass spectra were acquired on a Voyager DE-STR
Super MALDI time-of-flight instrument (Applied Biosys-
tems, Framingham,MA,USA).-Cyano-4-hydroxycinnamic
acid was re-crystallized in hot methanol and stored in
the dark. Before analysis of acetylated proteins and
peptides, a fresh solution of saturated -cyano-4-
hydroxycinnamic acid in water/ethanol/formic acid
45/45/10 (vol/vol) was prepared. Matrix solution (0.5
L) was mixed with sample (0.5 L), pipetted onto the
target and dried at RT. Mass calibration was performed
using an external calibrant (Applied Biosystems).
LC-ESI/MS and MS/MS
For the LC-ESI/MS analyses, an aliquot of the acety-
lated peptide sample was injected onto a Hypersil
RP-18 column (75 m i.d.  15 cm; LC Packings, San
Francisco, CA, USA) and eluted with a linear gradient
of 5% to 95% B in 30 min (A: 0.1% formic acid in water,
B: 0.1% formic acid in acetonitrile). The solvents deliv-
ered from the pumps were split before the sample
injector such that 200 nL/min were delivered to the
mass spectrometer.
Separation of HPG-derivatized peptides from an 8
L-aliquot, which had been incubated with 5 mM
dithioerythritol for 30 min at RT before analysis, was
achieved on a C18-PepMap column (5 m, 75 m i.d. 
150 mm, LC Packings); conditions: A: 0.1% formic acid
in water; B: 0.1% formic acid in acetonitrile; gradient: 0.3
L/min; 5% B, 5 min; 5%–95% B over 35 min.
For online analysis of the eluting peptides, the nano-
HPLC column was connected to an electrospray ioniza-
tion source on a quadrupole-time-of-flight instrument
(QTOF-I and QTOF-Micro, Micromass, Altrincham,
UK). Instrument conditions for QTOF-I: capillary 2800–
3095 V, sample cone 19–21 V, source temperature 80 °C,
scan: MS, m/z 300–4000 over 2 s, MS/MS, m/z 50–2000
over 2 s, collision energy 30 V. Conditions on QTOF-
Micro for MS: capillary voltage 3000 V, cone voltage 30
V, extraction voltage 2.5 V, collision energy 10 V, sourcetemperature 20 °C, and scan: m/z 400–1800 over 0.98 s;
alternatively for MS/MS: cone voltage 40 V, collision
energy 30 V, scan: m/z 80–2800 over 2 s. Data were
acquired using MassLynx 3.5 and deconvoluted via
MaxEnt3 (Micromass, Altrincham, UK).
Data Analysis
The relative abundances of HPG-derivatized peptides
were calculated from the sum of counts of the peptides
in the various charge states, with the total for unmod-
ified and modified peptides defining 100%. To deter-
mine the significance of the relative changes, the ratios
of the relative abundance of a specific peptide derived
from Ab-bound gp120 to the relative abundance of the
corresponding peptide derived from unbound gp120
were calculated. In cases where only one modification
state (either modified or unmodified) was observed the
relative abundance of this peptide was defined as 99%,
whereas the relative abundance of the complimentary
peptide (unmodified or modified) was defined as 1%
for calculation purposes only. A ratio of 1 would
indicate that the relative reactivity of an arginine resi-
due was equal in the presence and absence of the
antibody. The mean of all values was 0.87 with a
standard deviation of 0.33. Data points with a variation
from the mean of greater than 1 standard deviation, i.e.,
R480 and R476, were then omitted. The mean of the
remaining data points was calculated to be 0.98 with a
standard deviation of 0.14. Based on this standard
deviation, ratios within 0.98  0.14 indicated no signif-
icant change, changes within two standard deviation
changes were considered moderately significant, and
ratios with greater than 0.28 deviation from the mean
were termed significant.
Similarly, the relative reactivity of lysine residues
was determined as a ratio of the abundance of acety-
lated to trideuteroacetylated peptide. To determine
changes in reactivity of lysine residues, the ratios of
the relative reactivity of gp120 derivatized in the presence
of the MAb to the relative reactivity of gp120 in the
absence of MAbwere calculated. The reactivitywas consid-
ered unchanged for ratios with deviations within 20%
of 1, moderate for ratios with deviations within 20%
to 40% of 1 and significant for ratios with deviations
greater than 40%.
Residue Numbering System
The sequence of the HIV-1SF2 gp120 used in this study is
shown in Figure 1. The numbering system used is accord-
ing to Korber et al. [43]. In this system, the sequence of the
protein is numbered according to the sequence of the
protein in HIVHXB2CG (http://hiv-web.lanl.gov/content/
hiv-db/LOCATE_SEQ/locate.html; http://www.hiv.lanl.
gov/content/hiv-db/REVIEWS/HXB2.html). Insertions are
indicated as xxxa  AA where the inserted amino acid
is inserted after residue xxx. If more than one amino
acid is inserted, the residues are indicated sequentially
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inserted. Deletions are indicated by HXBC region num-
bers with deleted amino acid numbers in parentheses,
i.e., (del 460-461) or (460-461) for deletion of two
amino acids at positions 460 and 461.
Results and Discussion
To develop a better understanding of the correlation of
antigen structure and the neutralization potency of the
antibody, it is important to determine the epitope recog-
nized by the antibody using a full-length glycosylated
gp120 that closely resembles the wild-type protein. In this
study we used non-deglycosylated, non-truncated gp120
from recombinantly expressed HIV strain SF2gp120. To
characterize the epitope recognized by the antibody 559/
64-D, lysine and arginine residues in gp120 were chemi-
cally modified and their relative reactivities between
gp120 bound to MAb559/64-D and unbound gp120 were
determined. The recombinant HIV envelope protein gp120
of HIV strain SF2 is a major representative of the
  1  
HXBC2-env   MRVKEKYQHL WRWGWRWGTM LLGMLMIC
SF2-gp120   ---------- ---------- --------
17
HXBC2-env   THACVPTDPN PQEVVLVNVT ENFNMWKN
SF2-gp120   THACVPTDPN PQEVVLGNVT ENFNMWKN
141
HXBC2-env   NSSSGRMIME KGEIKNCSFN ISTSIRGK
SF2-gp120   NSSNWKEEI- KGEIKNCSFN ITTSIRDK
───────────────────────────────
602
HXBC2-env   PKVSFEPIPI HYCAPAGFAI LKCNNKTFN
SF2-gp120   PKVSFEPIPI HYCTPAGFAI LKCNNKTFN
572
HXBC2-env  VNFTDNAKTI IVQLNT--SV EINCTRPNN
SF2-gp120   DNFTNNAKTI IVQLNE--SV AINCTRPNN
                           |◄────
243
HXBC2-env  L---KQIASK LREQFGNNKT --IIFKQSS
SF2-gp120  L---EQIVKK LREQFGNNKT --IVFNQSS
                                          
604
HXBC2-env  NNTEGSDTIT LPCRIKQIIN MWQKVGKAM
SF2-gp120   --TKGNDTII LPCRIKQIIN MWQEVGKAM
────────────►|                 
374
HXBC2-env   GDMRDNWRSE LYKYKVVKIE PLGVAPTKA
SF2-gp120   GDMRDNWRSE LYKYKVIKIE PLGIAPTKA
Figure 1. Alignment of the sequences of reco
acids 31-509 of the env-precursor protein [54]
env-protein [43]. Arginine and lysine residues w
shown in red, residues with a slightly decrease
with no change in relative reactivity in blue, a
are shown in dark-green. Lysine and arginine r
sites in HIVSF2 gp120 as determined by mass sp
system used here, the annotation “405-407” in
residues (405-407) relative to the HXBc2 refere
SF2 gp120 sequence contains an additional T r
reference sequence [43].TCLA-strains and corresponds to amino acids 31-509 ofthe HIVSF2 env-protein. It contains 30 lysine residues
and 25 arginine residues (Figure 1).
Lysine Acetylation
Two acetylation steps were performed, the first with
acetic anhydride, and the second, with d6-acetic anhy-
dride. The relative reactivities of the lysine residues for
which peptides were observed was determined from
the ratios of the abundance of acetylated and trideu-
teroacetylated peptide, respectively, within one sample.
Ratios of the relative reactivity of gp120 derivatized in
the presence of the MAb to the relative reactivity of
gp120 in the absence of the MAb were used to deter-
mine the changes of reactivity upon binding of the MAb
559/64-D (Table 1). The calculation of the ratio of
relative reactivities results in a normalization of the
relative reactivities, thereby allowing the comparison of
the two experimental conditions of gp120 bound to the
MAb and free in solution. The ratio of 1 would indicate
that the relative reactivity of a specific residue did not
70
KLWVTVYY GVPVWKEATT TLFCASDAKA YDTEVHNVWA
KLWVTVYY GVPVWKEATT TLFCASDARA YDTEVHNVWA
041
QMHEDIIS LWDQSLKPCV KLTPLCVSLK CTDLKNDTNT
QMQEDIIS LWDQSLKPCV KLTPLCVTLN CTDLGKATNT
|◄──── Loop V1/V2 ───-
502
YAFFYKLD IIPIDNDTTS -----YKLTS CNTSVITQAC
NALFRNLD VVPIDNASTT TNYTNYRLIH CNRSVITQAC
──────────────────►|  
472
P-CTNVST VQCTHGIRPV VSTQLLLNGS LAEEEVVIRS
P-CTNVST VQCTHGIRPI VSTQLLLNGS LAEEEVVIRS
143
KRIRIQRG PGRAFVTIGK I-GNMRQAHC NISRAKWNNT
KSIYI--G PGRAFHTTGR IIGDIRKAHC NISRAQWNNT
─────  Loop V3 ──────────────►|  
504
PEIVTHSF NCGGEFFYCN STQLFNSTW- FNSTWSTEGS
PEIVMHSF NCRGEFFYCN TTQLFNNTWR LNH---TEG-
       |◄───────── Loop V4 ────
274
PISGQIRC SSNITGLLLT RD--GG-NSN NESEIFRPGG
PIGGQISC SSNITGLLLT RD--GGTNVT NDTEVFRPGG
                          |◄─Loop V5──►|
115
VVQREKR  
VVQREKR
nant HIV-1SF2 gp120 corresponding to amino
of the residues 1-511 of the reference HXBc2
a significantly decreased relative reactivity are
lative reactivity are shown in purple, residues
esidues with an increase in relative reactivity
es not detected are in orange. N-glycosylation
metry are italicized [11, 12]. In the numbering
tes that SF2 gp120 contains a deletion of three
equence and “ins 459a  T” indicates that the
e between residues 459 and 460 in the HXBc2SA TE
-- -E
DM VE
NM VE
VQ KE
IQ KE
────
G TG
G KG
N TR
N TR
-───
G GD
G GD
     
Y AP
Y AP
     
K RR
K RR
mbi
and
ith
d re
nd r
esidu
ectro
dica
nce s
esiduchange upon binding of the MAb, while a ratio of 0
in 2
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antibody. A ratio of greater than 1.0 indicates increased
accessibility/reactivity due to the presence of the MAb.
K409
Representative LC/ESI/MS spectra of the doubly-
charged peptide 404GTKGNDTIILPCR419405-407 after
derivatization of lysine residues, deglycosylation, and
reductive alkylation of the cysteine residues from the
Ab-Ag complex and from gp120 free in solution are
shown in Figure 2a and b, respectively. The absence of
an ion of m/z 744.49 in the spectrum of acetylated,
deglycosylated, and proteolyzed gp120 from the gp120:
MAb complex (Figure 2a) shows that, in the presence of
the antibody, derivatization of K409 did not occur
Table 1. Relative reactivities of lysine residues
Lysine
residuea Peptide sequence (HIVSF
155 154IKNCSFNITTSIR166
168, 171 167DKIQKE172
282 270VVIRSDNFTNNAKTIIVQLNE290
305 305KSIYIGPGR315 310-311
409 404GTKGNDTIILPCR419 405-407
432 430VGKAMYAPPIGGQISCSSNITGLLLTRDGGT
485, 487, 490,
500, 502
483LYKYKVIKIEPLGIAPTKAKRRVVQRE509
aResidue numbers are based on HIVHXBc2 gp120 as shown in Figure
bRatios of relative reactivity of gp120 derivatized in the presence of th
cReactivity was considered unchanged (-) for ratios with deviations with
of 1, and significant (s) for ratios with deviations greater than 60%.
Figure 2. Representative LC/ESI/MS spectra (s
peptide containing residues 404-419 405-407 w
absence (b) of the MAb. These spectra indicate
presence of the antibody.during the first step but was only achieved under
denaturing conditions, resulting in an ion of m/z 745.94.
In contrast, 57% of K409 was already seen derivatized
during the first step of acetylation when the antibody
was absent (Figure 2b, Supplemental Figure S-1, which
can be found in the electronic version of this article).
The relative reactivity of K409 changed from 0.75 for
gp120 free in solution to 0 for gp120 bound.
K432
Aca. 50% increase in reactivitywas observed for this residue
in the presence ofMAb559-64D. This increase in reactivity of
this residue may indicate that a conformational change
occurs in the gp120 in the presence of the antibody that leads
to an increased surface accessibility and/or reactivity.
Ratio of modified to
unmodified
in antibody-bound versus
antibody-free HIV-1 gp120b
Change of
reactivityc
1.18  0.05 -
1.18  0.1 -
1.11 -
1.16  0.4 -
0 s2
NDTE466 ins 459aT 1.56 m1
1.16  0.07 -
oted “HXBc2-env”).
b to relative reactivity of gp120 in absence of MAb.
0% of 1, moderate (m) for ratios with deviations within20% to 60%
f five individual spectra) of the doubly charged
sine residue 409 derivatized in presence (a) and
K409 was protected from derivatization in the2)
NVT
1 (den
e MAum o
ith ly
that
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and 502
The reactivities of these lysines were not affected,
within experimental error, by the presence/absence of
the antibody. This indicates that the antibody does not
interact with these residues.
In summary, of 12 lysine residues that were charac-
terized, the surface reactivity of one residue (K409) was
found to be significantly reduced by the presence of
559/64-D, and the surface reactivity of one residue
(K432) was found to be moderately enhanced in the
presence of the antibody. Additionally, modifications of
residues that lead to change of the formal charge on the
residue side chain may also influence the solubility of
Figure 3. Representative LC/ESI/MS spectra
477-485 with arginine residue 480 modified in
absence (c) without label, (d) with label) of the
phenylglyoxal the retention time of the peptide increthe modified protein, leading to reduced information
about the reactivity of some residues.
Arginine Hydroxyphenyl Glyoxylation
Arginine residues were modified with hydroxyphenyl-
glyoxal in antibody-bound gp120 and gp120 free in
solution. The relative abundances of HPG-derivatized
peptides were calculated from the sum of counts of the
peptides in the various charge states, with the total for
unmodified and modified peptides defining 100% (Table
2). Representative spectra from an LC/ESI/MS analysis of
the triply charged peptide 477DNWRSELYK485 are shown
in Figure 3. R476 was found in peptide 463-476 with
he triply charged peptide containing residues
presence (a) without label, (b) with label, and
b. Note that after derivatization with hydroxy-of t
the
MAases compared to the underivatized peptide.
1694 HAGER-BRAUN ET AL. J Am Soc Mass Spectrom 2010, 21, 1687–1698one missed cleavage arising from combined trypsin
and GluC proteolysis. This peptide also contained
R469. R469 was also observed by itself in peptide
463-473, in which no change in extent of modification
to R469 was observed between bound and unbound
gp120. Thus, changes in the relative extent of modi-
fication between bound and unbound gp120 peptide
463-476 was attributed to changes in the extent of
modification to R476. Peptides containing 13 of 25
arginine residues were observed whose sequences
were confirmed by MS/MS.
R456, R476, and R480
The reactivity of these residues were significantly re-
duced (by more than one standard deviation) in the
presence of 559/64-D, with R476 and 480 being most
strongly affected. The reactivity of R456 is less strongly
affected by the presence of the Ab (Figure 3, Supple-
Table 2. Relative reactivities of arginine residuesc,d
Arginine residuea
Ratio of modified to
unmodified in
antibody-bound
versus antibody- free
HIV-1 gp120 Changeb
59 1.11 m1
47EATTTLFCASDARAY61
166 0.92 -
160NITTSIR166
177 0.87 -
172ENALFRNL179
252c 0.81 m2
237/241GP-TNVST
VQCTHGIRPIVSTQLLL261
273 1.01 -
262NGSLAEEEVVIRS274
298 1.02 -
276NFTNNAKTI IVQLNE–SV
AINCTRPN300
335 1.18 -
332NISRAQW338
395a 1.05 -
392NNTWRL396ins
419 0.95 -
410GNDTIILPCRIK421
456d 0.78 m2
448NITGLLLT
RD–GGT456/462 ins 459aT
469 1.11 -
463NDTEVFRPGGG473
476 0.40 s2
463NDTEVFRPGGGDMR476
480 0.25 s2
477DNWRSE LYK485
aItalicized N indicates that this residue was originally glycosylated.
bm  moderate (between 1 and 2 standard deviations; s  strong
(greater than two standard deviations); -  no significant change.
cTwo peptides were found that included R252, one starting with AA 237
and the second starting with AA241.
dTwo peptides were found that included R456, one ending with AA 456
and the second ending with AA459a ins.mental Figure S-2). These residues are in the proteincore of gp120 (Figure 4a). It should be noted that R456
was observed in several peptides after PNGase F treat-
ment, 448-456, 448-459 ins 459a  T (one missed cleav-
age site) and 448-462 ins 459a  T (two missed cleavage
sites). The unmodified peptide dominated in all cases.
Peptide 448-462 ins 459a  T contains a glycosylation
site at N460 that is only partially glycosylated [11].
During deglycosylation with PNGaseF the glycosylated
asparagine residue will be transformed to an aspartic
acid residue, while the asparagine residue of the non-
glycosylated peptide will not be affected. Peptide 448-
462 ins 459a  T with N460 and peptide 448-462 ins
459a  T with D460 could be separated by 0.23 min by
reversed-phase chromatography. The sequence of these
peptides was confirmed by MS/MS (data not shown).
For all peptides, the ratios of modified to unmodified
peptides in the bound and unbound forms showed
moderate protection.
R59
The reactivity of R59 is moderately increased in the
presence of the Ab. The position of R59 in the gp120
structure was not determined in the solved structure of
the construct, which did not include the first 52 N-
terminal residues. It was also omitted from our compu-
tational model of HIVSF2 gp120 [9, 12]. Our results,
however, indicate that this residue is slightly more
accessible in the presence of MAb 559/64-D.
R252
This arginine exhibited slightly lower reactivity when
bound to the antibody. R252 is located spatially close to
A287 of the V3 loop. The slightly increased protection of
this residue may be due to movement of the V3 loop
and/or glycans upon Ab binding.
R166, 177, 273, 298, 335, 395a, 419, and 469
The relative reactivities of these arginines did not vary
significantly from the mean. Thus, the locations of these
residues are such that the reactivities are unaffected by
the presence of the antibody.
Peptides for the remaining 12 arginine residues were
not observed. One possible reason for this is the size of
the peptides formed during proteolysis may be too
small or too large to be analyzed. Blocked cleavage at
acetylated lysine can lead to large peptides. For exam-
ple, a complete digest of gp120 with LysC/AspNwould
result in arginine-containing peptides with a mass
smaller than 600 Da, and trypsin/Glu-C digestion can
still lead to peptides with a mass of over 4000 Da
containing two arginine residues. In summary, 13 of 25
arginine residues were characterized, and five of these
were affected by the binding of 559/64-D.
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Three-Dimensional Structure of gp120
Based on the high sequence homology between HIV
strains SF2 and HXBc2 (see Figure 1), the structural data
of the gp120 core of HIVHXBc2 [9], and the characteriza-
tion of the glycan chains of recombinantly expressed
HIVSF2 gp120, a molecular model of glycosylated full-
length gp120 was developed (Figure 4a) [12]. The model
is depicted to illustrate the extensive shielding of the
gp120 core by the carbohydrate moieties and the posi-
tion of the variable loops V1/V2, V3, V4, and V5. Using
this model, localization of the residues characterized in
this study is shown in Figure 4b (same orientation as in
Figure 4a) and in Figure 4c (gp120 tilted forwards by
90°), omitting the glycans for clarity. The amino acids
for which the relative reactivity was significantly re-
duced by the presence of the MAb form a cluster
around the CD4-binding site, predominantly on one
side of the CD4-BS cleft, and are indicative of the
epitope recognized by the MAb 559/64-D. The MAb-
Figure 4. (a) The structural model of glycosylat
by Zhu et al. [12] was used to depict the protein c
ribbons), and the glycan chains (stick models). Th
the bottom of gp120 (purple arrow) and CD4 en
The amino acids characterized in this study wer
surface model and the loops as ribbons. Residue
shown in red, residues with a slightly decreased
no change in relative reactivity in blue, and resid
in dark-green. Amino acids in light-yellow resid
structure of HIVHXBc2 gp120 [9]. The orientation
90° forwards such that an interacting CD4-mol
would be located “behind” gp120. Color code is
arginines, which were not verifiably detected
respectively.shielded residues R456, R476 and R480 are located inthe core of gp120 (as modeled as the surface described
in the caption of Figure 4), whereas K409 is within the
flexible loop V4, but within 8.8 Å of the significantly
affected R456 (C-atoms).
The position of residues R59, K500, and K502 could
not be determined because 52 residues at the N-terminus
and 19 residues at the C-terminus of the HIVHXBc2
gp120 core were deleted for the crystallization studies
and were also omitted from the computational model of
the HIVSF2 gp120 [9, 12]. However, all additional resi-
dues characterized in this study are exposed on the
protein surface.
The amino acids characterized in this study were
also mapped on the structure of the SIVgp120 core,
which was crystallized in the absence of interacting
proteins such as CD4 or Abs [27, 44]. Residues I469,
A486, and R490 corresponding to the significantly af-
fected residues R456, R476, and R480 in the HIVHXBc2
env-protein [27] are located within or in the vicinity of
the CD4-interaction site (Figure 5a, same orientation as
ll-length gp120 of HIV strain SF2 as determined
ray ribbon), the variable loops (blue and purple
del is oriented with the gp41-interaction site on
g its binding site from the top (gold arrow). (b)
ped to HIVSF2 gp120 with the protein core as a
a significantly decreased relative reactivity are
ve reactivity are shown in purple, residues with
with an increase in relative reactivity are shown
hin the CD4 binding area as found in the X-ray
e same as in (a). (c) The gp120-model was tilted
would stick out of the paper plane and gp41
(b). (d) Same view as in (c) with all lysines and
hese experiments colored in cyan and black,ed fu
ore (g
e mo
terin
e map
s with
relati
ues
e wit
is th
ecule
as in
in tfor Figure 4a), and the distances between these residues
.1696 HAGER-BRAUN ET AL. J Am Soc Mass Spectrom 2010, 21, 1687–1698are similar to the distances determined for HIVHXBc2
(I469–A486: 18.16Å; I469–R490: 18.67Å; A486–R490:
5.55Å between C-atoms). However, in the crystal
structure these residues are partly covered by the
residues N-terminal of the helix 1 (Figure 5c). Stricher
et al. recently studied the structural basis of immune
evasion at the CD4-BS on HIV-1 gp120 and found that
several antibodies recognize the CD4-BS, but are not
broadly neutralizing, and these less broadly neutraliz-
ing antibodies assumed a conformation that was poorly
compatible with the functional trimeric viral spike [24].
Although neutralizing antibodies such as 2F5 can
recognize a linear protein-based epitope on the env-
protein [45–47] (though the linear peptide correspond-
ing to the epitope cannot generate neutralizing antibod-
ies), the majority of broadly neutralizing antibodies
recognize conformational (e.g., 2F5) and/or discontin-
uous epitopes ([1, 14, 20] and references therein). Ac-
cording to the distribution of the amino acids in the
linear sequence of gp120, the residues with decreased
relative reactivity for derivatizing agents upon binding
of the MAb 559/64-D, the epitope recognized by this
neutralizing Ab is also discontinuous. Based on the
crystal structure of the gp120 core from the HIV strain
HXBc2 [9, 45] and the assignment of the immunogenic
areas “neutralizing face,” “non-neutralizing face,” and
“silent face” [17, 20], the MAb 559/64-D binds to the
CD4-BS within the neutralizing face on gp120 as in-
ferred from the significantly reduced reactivity of K409,
R456, R476, and R480. The structure of the Fab fragment
of MAb F105, another broadly neutralizing Ab that does
not neutralize primary isolates, has been published and
its interaction with the gp120 CD4-BS has been modeled
[36]. The MAb was predicted to interact with residues
255-7, 368, 370, 375, 384, 421, 470, and 473-477. Our
results indicate that 559/64-D binds in a similar, but not
Figure 5. (a) The structure of the glycosylated
protein core as gray ribbon and the carbohydrat
same as for the HIV gp120 core in Figure 4A.
sequence corresponding to the residues characte
of the SIV gp120 core. (c) Amino acids correspon
mapped to the surface model of the SIV gp120 co
affected by the MAb 559/64-D is as in Figure 4identical, manner in that R476 and 480 are significantlyaffected by the Ab, but R469 is not. In contrast, the
broadly neutralizing MAb b12 does not interact with
residues 473-476 (the N-terminal end of helix 5),
consistent with the hypothesis that interactions with
residues 473-477 may be a major difference between
antibodies recognizing primary isolates and those rec-
ognizing gp120 epitopes on TCLA strain [36].
As discussed previously, differences in the environ-
ment of specific residues, e.g., salt bridges, can lead to
differences in reactivity not directly associated with
surface reactivity (see, for example, [40, 48]). Conforma-
tional changes have been similarly invoked to explain
changes in differential reactivity of specific residues
[49]. Experimental evidence from a number of research-
ers indicates that gp120 undergoes a conformational
change upon CD4 binding [24, 50–53] and upon bind-
ing of certain antibodies [25]. Our results also implicate
conformational effects on our differential surface mod-
ification data. As residues distant from the CD4-BS
were also affected, this approach to epitope mapping is
also sensitive to factors that affect surface reactivity in
addition to direct interaction between the antigen and
the antibody. The complexity of the glycoprotein gp120
may complicate the differential reactivity approach to
epitope mapping in various ways. Due to the extensive
glycosylation of gp120, steric hindrance for the deriva-
tizing agent might lead to reduced reactivity of amino
acids, which do not interact with the Ab. In addition,
Ab binding to the CD4-BS might induce conformational
changes of the gp120 core, which results in newly
formed intermolecular interaction sites. Although the
reduced accessibilities of these residues would be spe-
cific for the Ab-bound conformation they would not be
indicative of the intermolecular interaction site between
Ab and antigen. Indeed, using a similar approach, we
have observed significant changes between chemical
ganded SIV gp120-core [32] is shown with the
ieties as tan stick models. The orientation is the
mino acids at the same position in the linear
in this study were mapped to the ribbon model
to the residues characterized in this study were
e color code of the relative reactivity of residuesunli
e mo
(b) A
rized
ding
re. Threactivity in HCV E2 glycoprotein in the presence and
1697J Am Soc Mass Spectrom 2010, 21, 1687–1698 MAPPING AN HIVgp120 EPITOPE BY MASS SPECTROMETRYabsence of an Ab that can only be explained by signif-
icant Ab-induced conformational changes [49]. How-
ever, comparison of the results obtained for the epitope
of the MAb 559/64-D and reports for epitopes of other
Abs in the literature show the validity of our approach
for epitope mapping using glycosylated full-length
gp120 [44, 46].
In summary, we conclude from our experiments of
chemical modification of lysine and arginine residues
followed by mass spectrometric analyses that the epitope
recognized by the MAb 559/64-D overlaps the CD4-
binding site of gp120. Moreover, binding of the MAb to
its antigen seems to have an effect on the conformation
of gp120.
As mentioned above, modifications of residues that
lead to change of the formal charge on the residue side
chain may also influence the solubility of the modified
protein, leading to reduced information about the reac-
tivity of some residues. We are currently investigat-
ing alternative derivatizing reagents to circumvent this
problem.
Acknowledgments
The authors acknowledge support in part for this research by the
Intramural Research Program of the National Institute of Environ-
mental Health Sciences/National Institutes of Health (z050150)
and the NIH/NHLBI (grant HL59725 to S.Z.-P).
Appendix A
Supplementary Material
Supplementary material associated with this article
may be found in the online version at doi:10.1016/
j.jasms.2010.03.031.
References
1. Zolla-Pazner, S. Identifying Epitopes of HIV-1 that Induce Protective
Antibodies. Nature Reviews Immunology 2004, 4(3), 199–210.
2. Poignard, P.; Klasse, P. J.; Sattentau, Q. J. Antibody Neutralization of
HIV-1. Immunol. Today 1996, 17(5), 239–246.
3. Center, R. J.; Leapman, R. D.; Lebowitz, J.; Arthur, L. O.; Earl, P. L.;
Moss, B. Oligomeric Structure of the Human Immunodeficiency Virus
Type I Envelope Protein on the Virion Surface. J. Virol. 2002, 76(15),
7863–7867.
4. Dalgleish, A. G.; Beverley, P. C. L.; Clapham, P. R.; Crawford, D. H.;
Greaves, M. F.; Weiss, R. A. The CD4 (T4) Antigen is an Essential
Component of the Receptor for the AIDS Retrovirus. Nature 1984,
312(5996), 763–767.
5. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.;
Hercend, T.; Gluckman, J. C.; Montagnier, L. Lymphocyte-T T4 Mole-
cule Behaves as the Receptor for Human Retrovirus LAV. Nature 1984,
312(5996), 767–768.
6. Gagne, N.Demonstration of a Thermoreversible Gel for the Prevention of HIV
and Herpes Transmission; Universite Laval: QC, Canada 2000; p. 111.
7. Zaitseva, M.; Peden, K.; Golding, H. HIV Coreceptors: Role of Structure,
Post-Translational Modifications, and Internalization in Viral-Cell Fu-
sion and as Targets for Entry Inhibitors. Biochim. Biophys. Acta– Biomem-
branes 2003, 1614(1), 51–61.
8. Starcich, B. R.; Hahn, B. H.; Shaw, G. M.; McNeely, P. D.; Modrow, S.;
Wolf, H.; Parks, E. S.; Parks, W. P.; Josephs, S. F.; Gallo, R. C.;
Wongstaal, F. Identification and Characterization of Conserved and
Variable Regions in the Envelope Gene of HTLV-III LAV, the Retrovirus
of AIDS. Cell 1986, 45(5), 637–648.
9. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.;
Hendrickson, W. A. Structure of an HIV gp120 Envelope Glycoprotein
in Complex with the CD4 Receptor and a Neutralizing Human Anti-
body. Nature 1998, 393(6686), 648–659.10. Leonard, C. K.; Spellman, M. W.; Riddle, L.; Harris, R. J.; Thomas, J. N.;
Gregory, T. J. Assignment of Intrachain Disulfide Bonds and Charac-
terization of Potential Glycosylation Sites of the Type-1 Recombinant
Human-Immunodeficiency-Virus Envelope Glycoprotein (gp120) Ex-
pressed in Chinese Hamster Ovary Cells. J. Biol. Chem. 1990, 265(18),
10373–10382.
11. Cutalo, J. M.; Deterding, L. J.; Tomer, K. B. Characterization of Glyco-
peptides from HIV-I-SF2 gp120 by Liquid Chromatography Mass
Spectrometry. J. Am. Soc. Mass Spectrom. 2004, 15(11), 1545–1555.
12. Zhu, X. G.; Borchers, C.; Bienstock, R. J.; Tomer, K. B. Mass Spectromet-
ric Characterization of the Glycosylation Pattern of HIV-gp120 Ex-
pressed in CHO cells. Biochemistry 2000, 39(37), 11194–11204.
13. Bouma, P.; Leavitt, M.; Zhang, P. F.; Sidorov, I. A.; Dimitrov, D. S.;
Quinnan, G. V. Multiple Interactions Across the Surface of the gp120
Core Structure Determine the Global Neutralization Resistance Pheno-
type of Human Immunodeficiency Virus Type 1. J. Virol. 2003, 77(14),
8061–8071.
14. Gorny, M. K.; Williams, C.; Volsky, B.; Revesz, K.; Cohen, S.; Polonis,
V. R.; Honnen, W. J.; Kayman, S. C.; Krachmarov, C.; Pinter, A.;
Zolla-Pazner, S. Human Monoclonal Antibodies Specific for Conformation-
Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus
Type 1 Primary Isolates from Various Clades. J. Virol. 2002, 76(18),
9035–9045.
15. Moore, J. P.; Sodroski, J. Antibody Cross-Competition Analysis of the
Human Immunodeficiency Virus Type 1 gp120 Exterior Envelope
Glycoprotein. J. Virol. 1996, 70(3), 1863–1872.
16. Nyambi, P. N.; Mbah, H. A.; Burda, S.; Williams, C.; Gorny, M. K.;
Nadas, A.; Zolla-Pazner, S. Conserved and Exposed Epitopes on Intact,
Native, Primary Human Immunodeficiency Virus Type 1 Virions of
Group M. J. Virol. 2000, 74(15), 7096–7107.
17. Wyatt, R.; Sodroski, J.; The HIV-1 Envelope Glycoproteins: Fusogens,
Antigens, and Immunogens. Science 1998, 280(5371), 1884–1888.
18. Zwick, M. B.; Kelleher, R.; Jensen, R.; Labrijn, A. F.; Wang, M.; Quinnan,
G. V.; Parren, P.; Burton, D. R. A Novel Human Antibody Against
Human Immunodeficiency Virus Type 1 gp120 is V1, V2, and V3 Loop
Dependent and Helps Delimit the Epitope of the Broadly Neutralizing
Antibody Immunoglobulin G1 b12. J. Virol. 2003, 77(12), 6965–6978.
19. Zwick, M. B.; Parren, P.; Saphire, E. O.; Church, S.; Wang, M.; Scott, J. K.;
Dawson, P. E.; Wilson, I. A.; Burton, D. R. Molecular Features of the
Broadly Neutralizing Immunoglobulin G1 b12 Required for Recogni-
tion of Human Immunodeficiency Virus Type 1 gp120. J. Virol. 2003,
77(10), 5863–5876.
20. Wyatt, R.; Kwong, P. D.; Desjardins, E.; Sweet, R. W.; Robinson, J.;
Hendrickson, W. A.; Sodroski, J. G. The Antigenic Structure of the HIV
gp120 Envelope Glycoprotein. Nature 1998, 393(6686), 705–711.
21. Nunberg, J. H.; Follis, K. E.; Trahey, M.; LaCasse, R. A. Turning a corner
on HIV neutralization? Microb. Infect. 2000, 2(2), 213–221.
22. Myszka, D. G.; Sweet, R. W.; Hensley, P.; Brigham-Burke, M.; Kwong,
P. D.; Hendrickson, W. A.; Wyatt, R.; Sodroski, J.; Doyle, M. L.
Energetics of the HIV gp120-CD4 Binding Reaction. Proc. Natl. Acad. Sci.
U.S.A. 2000, 97(16), 9026–9031.
23. Xiang, S. H.; Kwong, P. D.; Gupta, R.; Rizzuto, C. D.; Casper, D. J.;
Wyatt, R.; Wang, L. P.; Hendrickson, W. A.; Doyle, M. L.; Sodroski, J.
Mutagenic Stabilization and/or Disruption of a CD4-Bound State
Reveals Distinct Conformations of the Human Immunodeficiency Virus
Type 1 gp120 Envelope Glycoprotein. J. Virol. 2002, 76(19), 9888–9899.
24. Stricher, F.; Huang, C. C.; Descours, A.; Duquesnoy, S.; Combes, O.;
Decker, J. M.; Do Kwon, Y.; Lusso, P.; Shaw, G. M.; Vita, C.; Kwong,
P. D.; Martin, L. Combinatorial Optimization of a CD4-Mimetic Mini-
protein and Cocrystal Structures with HIV-1 gp120 Envelope Glycop-
rotein. J. Mol. Biol. 2008, 382(2), 510–524.
25. Chen, L.; Kwon, Y. D.; Zhou, T. Q.; Wu, X. L.; O’Dell, S.; Cavacini, L.; Hessell,
A. J.; Pancera,M.; Tang,M.; Xu, L.; Yang,Z.Y.; Zhang,M.Y.;Arthos, J.; Burton,
D. R.; Dimitrov, D. S.; Nabel, G. J.; Posner, M. R.; Sodroski, J.; Wyatt, R.;
Mascola, J. R.; Kwong, P. D. Structural Basis of Immune Evasion at the Site of
CD4 Attachment on HIV-1 gp120. Science 2009, 326(5956), 1123–1127.
26. Pan, Y. P.; Ma, B. Y.; Keskin, O.; Nussinov, R. Characterization of the
Conformational State and Flexibility of HIV-1 Glycoprotein gp120 Core
Domain. J. Biol. Chem. 2004, 279(29), 30523–30530.
27. Chen, B.; Vogan, E. M.; Gong, H. Y.; Skehel, J. J.; Wiley, D. C.; Harrison,
S. C. Structure of an Unliganded Simian Immunodeficiency Virus gp120
Core. Nature 2005, 433(7028), 834–841.
28. McKeating, J. A.; Thali, M.; Furman, C.; Karwowska, S.; Gorny, M. K.;
Cordell, J.; Zolla-Pazner, S.; Sodroski, J.; Weiss, R. A. Amino Acid
Residues of the Human Immunodeficiency Virus Type I gp120Ccritical
for the Binding of Rat and Human Neutralizing Antibodies that Block
the gp120-sCD4 Interaction. Virology 1992, 190(1), 134–142.
29. Karwowska, S.; Gorny, M. K.; Buchbinder, A.; Gianakakos, V.; Williams,
C.; Fuerst, T.; Zolla-Pazner, S. Production of Human Monoclonal
Antibodies Specific for Conformational and Linear Non-V3 Epitopes of
gp120. AIDS Res. Hum. Retrovir. 1992, 8(6), 1099–1106.
30. Chien, P. C.; Cohen, S.; Tuen, M.; Arthos, J.; Chen, P. D.; Patel, S.; Hioe,
C. E. Human Immunodeficiency Virus Type 1 Evades T-Helper Re-
sponses by Exploiting Antibodies that Suppress Antigen Processing.
J. Virol. 2004, 78(14), 7645–7652.
31. Li, H. L.; Chien, P. C.; Tuen, M.; Visciano, M. L.; Cohen, S.; Blais, S.; Xu,
C. F.; Zhang, H. T.; Hioe, C. E. Identification of an N-Linked Glycosyl-
ation in the C4 Region of HIV-1 Envelope gp120 that is Critical for
Recognition of Neighboring CD4 T Cell Epitopes. J. Immunol. 2008,
180(6), 4011–4021.
1698 HAGER-BRAUN ET AL. J Am Soc Mass Spectrom 2010, 21, 1687–169832. Li, H. L.; Xu, C. F.; Blais, S.; Wan, Q.; Zhang, H. T.; Landry, S. J.; Hioe,
C. E. Proximal Glycans Outside of the Epitopes Regulate the Presenta-
tion of HIV-1 Envelope gp120 Helper Epitopes. J. Immunol. 2009,
182(10), 6369–6378.
33. Visciano, M. L.; Tuen, M.; Gorny, M. K.; Hioe, C. E. In Vivo Alteration
of Humoral Responses to HIV-1 Envelope Glycoprotein gp120 by
Antibodies to the CD4-Binding Site of gp120. Virology 2008, 372(2),
409–420.
34. Nandi, A.; Lavine, C. L.; Wang, P. C.; Lipchina, I.; Goepfert, P. A.; Shaw,
G. M.; Tomaras, G. D.; Montefiori, D. C.; Haynes, B. F.; Easterbrook, P.;
Robinson, J. E.; Sodroski, J. G.; Yang, X. Z.; and the NIAID Center for
HIV/AIDS Vaccine Immunology. Epitopes for Broad and Potent Neu-
tralizing Antibody Responses During Chronic Infection with Human
Immunodeficiency Virus Type 1. Virology 2010, 396(2), 339–348.
35. Stamatatos, L.; Chengmayer, C. Structural Modulations of the Envelope
gp120 Glycoprotein of Human-Immunodeficiency-Virus Type-1 Upon
Oligomerization and Differential V3 Loop Epitope Exposure of Isolates
Displaying Distinct Tropism Upon Virion-Soluble Receptor-Binding.
J. Virol. 1995, 69(10), 6191–6198.
36. Wilkinson, R. A.; Piscitelli, C.; Teintze, M.; Cavacini, L. A.; Posner,
M. R.; Lawrence, C. M.; Structure of the Fab Fragment of F105, a Broadly
Reactive Anti-Human Immunodeficiency Virus (HIV) Antibody that
Recognizes the CD4 Binding Site of HIV Type 1 gp120. J. Virol. 2005,
79(20), 13060–13069.
37. Glocker, M. O.; Borchers, C.; Fiedler, W.; Suckau, D.; Przybylski, M.
Molecular Characterization of Surface-Topology in Protein Tertiary
Structures by Aminoacylation and Mass-Spectrometric Peptide Map-
ping. Bioconj. Chem. 1994, 5(6), 583–590.
38. Hochleitner, E. O.; Borchers, C.; Parker, C.; Bienstock, R. J.; Tomer, K. B.
Characterization of a Discontinuous Epitope of the Human Immuno-
deficiency Virus (HIV) Core Protein p24 by Epitope Excision and
Differential Chemical Modification Followed by Mass Spectrometric
Peptide Mapping Analysis. Protein Sci. 2000, 9(3), 487–496.
39. Steiner, R. F.; Albaugh, S.; Fenselau, C.; Murphy, C.; Vestling, M. A
Mass-Spectrometry Method for Mapping the Interface Topography of
Interacting Proteins, Illustrated by the Melittin-Calmodulin System.
Anal. Biochem. 1991, 196(1), 120–125.
40. Suckau, D.; Mak, M.; Przybylski, M. Protein Surface Topology-Probing
by Selective Chemical Modification and Mass-Spectrometric Peptide
Mapping. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(12), 5630–5634.
41. Hager-Braun, C.; Tomer, K. B. Characterization of the Tertiary Structure
of Soluble CD4 Bound to Glycosylated Full-Length HIVgp120 by
Chemical Modification of Arginine Residues and Mass Spectrometric
Analysis. Biochemistry 2002, 41(6), 1759–1766.
42. Wood, T. D.; Guan, Z. Q.; Borders, C. L.; Chen, L. H.; Kenyon, G. L.;
McLafferty, F. W. Creatine Kinase: Essential Arginine Residues at the
Nucleotide Binding Site Identified by Chemical Modification and
High-Resolution Tandem Mass Spectrometry. Proc. Natl. Acad. Sci.
U.S.A. 1998, 95(7), 3362–3365.43. Korber, B. T.; Foley, B. T.; Kuiken, C. L.; Pillai, S. K.; Sodroski, J. G. Numbering
Positions in HIV Relative to HXB2CG. 1998 [cited 1998; available from:
http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/1998/
III/HXB2.pdf.
44. Hager-Braun, C.; Katinger, H.; Tomer, K. B. The HIV-Neutralizing
Monoclonal Antibody 4E10 Recognizes N-Terminal Sequences on the
Native Antigen. J. Immunol. 2006, 176(12), 7471–7481.
45. Kwong, P. D.; Wyatt, R.; Majeed, S.; Robinson, J.; Sweet, R. W.; Sodroski,
J.; Hendrickson, W. A. Structures of HIV-1 gp120 Envelope Glycopro-
teins from Laboratory-Adapted and Primary Isolates. Structure 2000,
8(12), 1329–1339.
46. Parker, C. E.; Deterding, L. J.; Hager-Braun, C.; Binley, J. M.; Schulke,
N.; Katinger, H.; Moore, J. P.; Tomer, K. B. Fine Definition of the Epitope
on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1
for the Neutralizing Monoclonal Antibody 2F5. J. Virol. 2001, 75(22),
10906–10911.
47. Zwick, M. B.; Labrijn, A. F.; Wang, M.; Spenlehauer, C.; Saphire, E. O.;
Binley, J. M.; Moore, J. P.; Stiegler, G.; Katinger, H.; Burton, D. R.;
Parren, P. Broadly Neutralizing Antibodies Targeted to the Membrane-
Proximal External Region of Human Immunodeficiency Virus Type 1
Glycoprotein gp41. J. Virol. 2001, 75(22), 10892–10905.
48. Hobbs, C. A.; Deterding, L. J.; Perera, L.; Bobay, B. G.; Thompson, R. J.;
Darden, T. A.; Cavanagh, J.; Tomer, K. B. Structural Characterization of
the Conformational Change in Calbindin-D-28k upon Calcium Binding
Using Differential Surface Modification Analyzed by Mass Spectrome-
try. Biochemistry 2009, 48(36), 8603–8614.
49. Iacob, R. E.; Keck, Z.; Olson, O.; Foung, S. K. H.; Tomer, K. B. Structural
Elucidation of Critical Residues Involved in Binding of Human Mono-
clonal Antibodies to Hepatitis C Virus E2 Envelope Glycoprotein.
Biochim. Biophys. Acta–Proteins and Proteomics 2008, 1784(3), 530–542.
50. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 Entry
Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G
Protein-Coupled Receptor. Science 1996, 272(5263), 872–877.
51. Lusso, P.; HIV and the Chemokine System: 10 Years Later. EMBO J.
2006, 25(3), 447–456.
52. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J. M.; Olson, W. C.; Allaway,
G. P.; ChengMayer, C.; Robinson, J.; Maddon, P. J.; Moore, J. P.
CD4-Dependent, Antibody-Sensitive Interactions Between HIV-1 and
Its Coreceptor CCR-5. Nature 1996, 384(6605), 184–187.
53. Wu, L. J.; Gerard, N. P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.;
Borsetti, A.; Cardoso, A. A.; Desjardin, E.; Newman, W.; Gerard, C.;
Sodroski, J. CD4-Induced Interaction of Primary HIV-1 gp120 Glycopro-
teins with the Chemokine Receptor CCR-5. Nature 1996, 384(6605),
179–183.
54. Sanchezpescador, R.; Power, M. D.; Barr, P. J.; Steimer, K. S.; Stempien,
M. M.; Brownshimer, S. L.; Gee, W. W.; Renard, A.; Randolph, A.; Levy,
J. A.; Dina, D.; Luciw, P. A. Nucleotide Sequence and Expression of an
AIDS-Associated Retrovirus (ARV-2). Science 1985, 227(4686), 484–492.
